BioSpace News Archive

Placental insufficiency is a complication of pregnancy, wherein the placenta is unable to deliver adequate nutrition to the fetus.

Microalbuminuria is a condition that affects the kidney and restricts in retaining serum albumin, which is considered as a vital factor for the kidney to maintain its overall health of the body.

Oxehealth have announced that the company has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

Imara Inc. today reported financial results for the year ended December 31, 2020 and reviewed recent business highlights.

Trevena to host conference call on March 9 th , 2021, at 8:00 a.m. ET --

ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMab TM platform, to better serve researchers in in vitro diagnostic, and antibody drug and therapeutic discovery market

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first of 40 patients in its Phase II COVID-19 study.

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the administration of the first dose of CRX100 to a volunteer in the ongoing Phase 1 clinical trial in patients with refractory solid tumors.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from preclinical studies of KER-050

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced the grants of inducement restricted stock units to nine new employees in connection with their employment with UroGen.